Pursuant to Regulation 29 of the Listing Regulations, Ajanta Pharma has informed that a Meeting of the Board of Directors of the Company will be held on Friday, 30th October 2026, to consider and approve unaudited consolidated and standalone financial results of the Company for the second quarter and half year ended 30th September 2026.
The above information is a part of company’s filings submitted to BSE.